| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 05/26/2006 | WO2006055455A1 Method for treating hiv infection through co-administration of tipranavir and darunavir |
| 05/26/2006 | WO2006055435A1 2-aminonaphthalene derivatives and related glycogen phosphorylase inhibitors |
| 05/26/2006 | WO2006055434A2 Macrocyclic tertiary amine beta-secretase inhibitors for the treatment of alzheimer's disease |
| 05/26/2006 | WO2006055412A1 Methods of treating erythropoietin-resistance |
| 05/26/2006 | WO2006055404A2 Compounds for targeting mechanisms implicated in the progression of stroke |
| 05/26/2006 | WO2006055359A1 Mixed antibiotic codrugs |
| 05/26/2006 | WO2006055268A2 Pyrimidothienoindazoles capable of inhibiting tyrosine kinases of the epidermal growth factor |
| 05/26/2006 | WO2006055216A2 Vulnerable plaque treatment |
| 05/26/2006 | WO2006055187A1 Sulfonyl-substituted bicyclic compounds as modulators of ppar |
| 05/26/2006 | WO2006055070A2 Novel lincomycin derivatives possessing antibacterial activity |
| 05/26/2006 | WO2006055008A2 Implantable sensors and implantable pumps and anti-scarring agents |
| 05/26/2006 | WO2006054938A1 Gaba-steroid antagonists and their use for the treatment of cns disorders |
| 05/26/2006 | WO2006054912A1 Aryl(hetaryl)-3-aminomethyl-quinilone-2 derivatives in the form of no-synthetase i and cyclooxygenase-2 nhibitors, methods for the production thereof and compositions based thereon |
| 05/26/2006 | WO2006054793A1 Benzofuran compound and pharmaceutical composition containing the same |
| 05/26/2006 | WO2006054788A1 METHOD OF SCREENING COMPOUND REGULATING THE TRANSLATION OF SPECIFIC mRNA |
| 05/26/2006 | WO2006054773A1 Activation of caspase in the cell division stage of cancer cells and utilization of caspase inhibitor in anticancer agent and so on |
| 05/26/2006 | WO2006054770A1 Novel map kinase kinase kinase (mapkkk) |
| 05/26/2006 | WO2006054757A1 Caspase inhibitor |
| 05/26/2006 | WO2006054710A1 Agent for ameliorating the maximum passage time through digestive tract, agent for ameliorating passage time through digestive tract and preventive for colon cancer |
| 05/26/2006 | WO2006054652A1 Amide compound |
| 05/26/2006 | WO2006054629A1 1-SUBSTITUTED-3-β-D-GLUCOPYRANOSYLATED NITROGENOUS HETERO- CYCLIC COMPOUNDS AND MEDICINES CONTAINING THE SAME |
| 05/26/2006 | WO2006054625A1 Cancer-cell-specific cytostatic agent |
| 05/26/2006 | WO2006054624A1 Adhesion preventive and method of preventing adhesion |
| 05/26/2006 | WO2006054623A1 Novel pyridonecarboxylic acid derivatives or salts thereof |
| 05/26/2006 | WO2006054560A1 Aromatic amide derivatives, medicinal compositions containing the same, medical uses of both |
| 05/26/2006 | WO2006054555A1 Medicinal composition for treating cancer or diabetes |
| 05/26/2006 | WO2006054536A1 Therapeutic agent for urolithiasis |
| 05/26/2006 | WO2006054530A1 Composition for promoting osteogenesis and increasing bone mineral content |
| 05/26/2006 | WO2006054514A1 Preventive or therapeutic pharmaceutical composition for neuropathic pain |
| 05/26/2006 | WO2006054513A1 Preventive or therapeutic agent for neuropathic pain |
| 05/26/2006 | WO2006054456A1 Crystal of two-ring heterocyclic sulfonamide compound |
| 05/26/2006 | WO2006054429A1 Oral composition containing difructose anhydride |
| 05/26/2006 | WO2006054396A1 Cyclic isodityrosine derivatives |
| 05/26/2006 | WO2006054370A1 Gluconeogenesis inhibiting agent |
| 05/26/2006 | WO2006054319A2 Use of chitooligomer formulations to modify abnormal activity of chitinase like proteins |
| 05/26/2006 | WO2006054316A1 Method(s) of preparation, stabilization, composition, and administration of gamma-linolenic acid for brain tumors |
| 05/26/2006 | WO2006054315A1 Nonaqueous liquid parenteral aceclofenac formulation |
| 05/26/2006 | WO2006054314A1 Polymorphic forms of imatinib mesylate |
| 05/26/2006 | WO2006054312A1 Ammonium compounds for treating psoriasis and eczema |
| 05/26/2006 | WO2006054308A2 Stable atorvastatin formulations |
| 05/26/2006 | WO2006054307A2 Controlled absorption of statins in the intestine |
| 05/26/2006 | WO2006054304A2 Use of lipid conjugates in the treatment of disease |
| 05/26/2006 | WO2006054298A2 Glycogen synthase kinase-3 inhibitors |
| 05/26/2006 | WO2006054175A2 Stable dosage forms of acid labile drug |
| 05/26/2006 | WO2006054166A1 Drugs and prodrugs useful for the treatment of energy balance in ruminants |
| 05/26/2006 | WO2006054165A1 Pharmaceutical compositions of alendronic acid and processes for their preparation |
| 05/26/2006 | WO2006054162A1 Azabicyclic muscarinic receptor antagonists |
| 05/26/2006 | WO2006054152A1 Monocompartment osmotic-controlled delivery system of doxazosin |
| 05/26/2006 | WO2006054143A1 Polymorphs of {5-[3-(4,6-difluoro-1h-benzoimidazol-2-yl)-1h-indazol-5-yl]-4-methyl-pyridin-3-ylmethyl}-ethyl-amine |
| 05/26/2006 | WO2006054120A1 Dry powder comprising levothyroxine sodium administered via inhalator |
| 05/26/2006 | WO2006054119A1 Topical formulations for use in the treatment or prevention of dermatological conditions |
| 05/26/2006 | WO2006054110A2 Immunotherapeutic agent |
| 05/26/2006 | WO2006053912A1 Formulations comprising ceramides and/or pseudoceramides and (alpha-)bisabolol for combating skin damage |
| 05/26/2006 | WO2006053910A1 Biphosphonic compounds for preventing or limiting fixing of macromolecules, micro-organisms and biofilm on solid, in particular metal or mineral surfaces |
| 05/26/2006 | WO2006053903A2 Low-molecular inhibitors of cytohesin-family guanine nucleotide exchange factors |
| 05/26/2006 | WO2006053899A1 Cabergoline preparation method |
| 05/26/2006 | WO2006053860A1 Isoxazolic derivative to relieve neuropathic pain |
| 05/26/2006 | WO2006053791A2 Compounds that modulate ppary type receptors, and use thereof in cosmetic or pharmaceutical compositions |
| 05/26/2006 | WO2006053790A1 Use of compounds of the n-acylaminoamide family as soothing or calming agents |
| 05/26/2006 | WO2006053789A1 Protection of the skin against deterioration linked to a stress-induced dysfunction of the apoptotic and immune defence processes |
| 05/26/2006 | WO2006053785A1 Radiolabelled quinoline-based ligands for the 5-ht6 receptor functionality |
| 05/26/2006 | WO2006053784A2 1,7-naphthyridines as pde4 inhibitors |
| 05/26/2006 | WO2006053780A1 Crystalline aripiprazole solvates |
| 05/26/2006 | WO2006053766A1 Methods for purifying trans-(-)-δ9-tetrahydrocannabinol and trans-(+)-δ9-tetrahydrocannabinol |
| 05/26/2006 | WO2006053760A1 Pharmaceutical compositions comprising (+) - (2s, 3s) - 2 - (chlorophenyl) - 3, 5, 5-trimethhyl-2-morpholinol |
| 05/26/2006 | WO2006053755A1 Pharmaceutical compositions comprising a camtothecin derivate |
| 05/26/2006 | WO2006053754A1 COMBINATIONS OF ANTI-ATHEROSCLEROTIC PEPTIDES AND AN mTOR INHIBITING AGENT AND THEIR METHODS OF USE |
| 05/26/2006 | WO2006053748A1 Substituted [(phenylethanoyl)amino] benzamides and the use thereof in the treatment of inflammatory and cardio-vascular diseases |
| 05/26/2006 | WO2006053707A1 Novel derivatives of porphyrin, particularly chlorins and/or bacteriochlorins, and uses thereof in photodynamic therapy |
| 05/26/2006 | WO2006053699A1 Pharmaceutical composition comprising a macrolide t-cell immunomodulator and anti-photoaging agent |
| 05/26/2006 | WO2006053680A1 Ex vivo cancer diagnostic method |
| 05/26/2006 | WO2006053649A1 Method for the detection of cancer |
| 05/26/2006 | WO2006053637A1 Preparation containing oxidized flavonoid derivatives |
| 05/26/2006 | WO2006053556A1 Treatment of neuropathic pain, fibromyalgia or rheumatoid arthritis |
| 05/26/2006 | WO2006053555A2 Pyrazol-3-one and/or pyridazin-3-one derivatives used as inhibitors of lysyl oxidase |
| 05/26/2006 | WO2006053487A1 The use of vegetable anthraquinone derivatives and vegetable polysaccharides for treating human immunodeficiency virus (hiv) |
| 05/26/2006 | WO2006053428A1 Compositions comprising scyllo-inositol derivatives and methods to treat disorders of protein aggregation |
| 05/26/2006 | WO2006053390A1 A method of modulating b cell functioning |
| 05/26/2006 | WO2006053383A1 Bioactive compositions |
| 05/26/2006 | WO2006053379A1 Improved nutraceutical composition |
| 05/26/2006 | WO2006045119A2 Improved inhibitors for the soluble epoxide hydrolase |
| 05/26/2006 | WO2006043260A3 Orally effective cannabinoid analogs |
| 05/26/2006 | WO2006036928A3 Inhibitors of matrix metalloproteinases to treat neurological disorders |
| 05/26/2006 | WO2006036743A3 Halocombstatins and methods of synthesis thereof |
| 05/26/2006 | WO2006034446A3 Pyridine derivatives for inhibiting human stearoyl-coa-desaturase |
| 05/26/2006 | WO2006034262A3 Method and composition for treating patients undergoing kidney dialysis |
| 05/26/2006 | WO2006029179A3 Substituted piperazine compounds and their use as fatty acid oxidation inhibitors |
| 05/26/2006 | WO2006029153A3 Monocyclic anilide spirolactam cgrp receptor antagonists |
| 05/26/2006 | WO2006028830A3 Opioid dosage forms having dose proportional steady state cave and auc and less than dose proportional single dose cmax |
| 05/26/2006 | WO2006027052A3 (halobenzyloxy) benzylamino-propanamides as sodium and/or calcium channel selective modulators |
| 05/26/2006 | WO2006026760A3 1-amino imidazo-containing compounds and methods |
| 05/26/2006 | WO2006026389A3 Ceramide derivatives as modulators of immunity and autoimmunity |
| 05/26/2006 | WO2006026316A3 Prodrug substituted benzoxazoles as estrogenic agents |
| 05/26/2006 | WO2006024931A3 Therapeutic combinations comprising a selective estrogen receptor modulator and a selective androgen receptor modulator |
| 05/26/2006 | WO2006024881A3 Multiparticulates of preferably an opioid, and method of manufacturing using extrusion |
| 05/26/2006 | WO2006024486A3 Amide derivatives of 3-phenyl dihydropyrimido[4,5-d]pyrimidinones, their manufacture and use as pharmaceutical agents |
| 05/26/2006 | WO2006022901A3 The use of purine nucleosides to stimulate na/k atpase and to treat or prevent shock |
| 05/26/2006 | WO2006021007A3 Effervescent composition including alternative hormone replacement therapy agent |
| 05/26/2006 | WO2006020853A3 Pharmaceutical composition and method for treating neurodegenerative disorders |
| 05/26/2006 | WO2006019586A3 Method of treating trauma or sepsis |